Transgene SA (TNG) - Total Assets
Based on the latest financial reports, Transgene SA (TNG) holds total assets worth €138.83 Million EUR (≈ $162.30 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See how leveraged is Transgene SA's balance sheet to measure how much of total assets are equity-financed.
Transgene SA - Total Assets Trend (1997–2025)
This chart illustrates how Transgene SA's total assets have evolved over time, based on quarterly financial data. Explore TNG long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Transgene SA - Asset Composition Analysis
Current Asset Composition (December 2025)
Transgene SA's total assets of €138.83 Million consist of 84.8% current assets and 15.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 4.8% |
| Accounts Receivable | €3.65 Million | 2.6% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €49.00K | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (1997–2025)
This chart illustrates how Transgene SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see TNG market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Transgene SA's current assets represent 84.8% of total assets in 2025, an increase from 58.5% in 1997.
- Cash Position: Cash and equivalents constituted 4.8% of total assets in 2025, down from 47.3% in 1997.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1997.
- Asset Diversification: The largest asset category is accounts receivable at 2.6% of total assets.
Transgene SA Competitors by Total Assets
Key competitors of Transgene SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Transgene SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.62 | 1.48 | 2.25 |
| Quick Ratio | 9.62 | 1.48 | 2.06 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €105.45 Million | €6.68 Million | €17.06 Million |
Transgene SA - Advanced Valuation Insights
This section examines the relationship between Transgene SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.80 |
| Latest Market Cap to Assets Ratio | 1.54 |
| Asset Growth Rate (YoY) | 229.2% |
| Total Assets | €138.83 Million |
| Market Capitalization | $213.47 Million USD |
Valuation Analysis
Above Book Valuation: The market values Transgene SA's assets above their book value (1.54x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Transgene SA's assets grew by 229.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Transgene SA (1997–2025)
The table below shows the annual total assets of Transgene SA from 1997 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €138.83 Million ≈ $162.30 Million |
+229.17% |
| 2024-12-31 | €42.17 Million ≈ $49.31 Million |
-6.73% |
| 2023-12-31 | €45.22 Million ≈ $52.86 Million |
-31.94% |
| 2022-12-31 | €66.44 Million ≈ $77.67 Million |
-34.76% |
| 2021-12-31 | €101.84 Million ≈ $119.06 Million |
+19.17% |
| 2020-12-31 | €85.45 Million ≈ $99.90 Million |
-26.00% |
| 2019-12-31 | €115.48 Million ≈ $135.00 Million |
+6.39% |
| 2018-12-31 | €108.54 Million ≈ $126.90 Million |
+7.60% |
| 2017-12-31 | €100.87 Million ≈ $117.93 Million |
-17.96% |
| 2016-12-31 | €122.95 Million ≈ $143.74 Million |
+21.89% |
| 2015-12-31 | €100.87 Million ≈ $117.93 Million |
-28.44% |
| 2014-12-31 | €140.95 Million ≈ $164.79 Million |
+12.00% |
| 2013-12-31 | €125.85 Million ≈ $147.13 Million |
-21.57% |
| 2012-12-31 | €160.46 Million ≈ $187.60 Million |
-17.11% |
| 2011-12-31 | €193.58 Million ≈ $226.32 Million |
-13.46% |
| 2010-12-31 | €223.69 Million ≈ $261.51 Million |
+126.72% |
| 2009-12-31 | €98.66 Million ≈ $115.35 Million |
-22.10% |
| 2008-12-31 | €126.65 Million ≈ $148.06 Million |
-1.30% |
| 2007-12-31 | €128.31 Million ≈ $150.01 Million |
+293.54% |
| 2006-12-31 | €32.60 Million ≈ $38.12 Million |
+27.85% |
| 2004-12-31 | €25.50 Million ≈ $29.81 Million |
-44.34% |
| 2003-12-31 | €45.82 Million ≈ $53.57 Million |
-31.49% |
| 2002-12-31 | €66.88 Million ≈ $78.19 Million |
-22.61% |
| 2001-12-31 | €86.42 Million ≈ $101.03 Million |
+80.27% |
| 2000-12-31 | €47.94 Million ≈ $56.04 Million |
-28.33% |
| 1999-12-31 | €66.89 Million ≈ $78.20 Million |
-21.14% |
| 1998-12-31 | €84.82 Million ≈ $99.16 Million |
+181.28% |
| 1997-12-31 | €30.15 Million ≈ $35.25 Million |
-- |
About Transgene SA
Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of ovarian cancer, and head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillom… Read more